TNF and rheumatoid arthritis: The latest American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) guidelines for the management of RA do not specifically consider patients with RA-ILD, suggesting the need for a multidisciplinary approach [37,38], while the National Institute for Health and Care Excellence (NICE) and Spanish Society of Rheumatology have proposed national recommendations, suggesting the use of abatacept and rituximab in patients with RA-ILD, and advising against the use of TNF inhibitors [39,40].